Bioporto A/S
CSE:BIOPOR
Bioporto A/S
CSE:BIOPOR
Price:
1
DKK
1.32%
Market Closed
Market Cap:
kr495.1m
Relative Value
The Relative Value of one
BIOPOR
stock under the Base Case scenario is
0.6
DKK.
Compared to the current market price of 1 DKK,
Bioporto A/S
is
Overvalued by 40%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BIOPOR
Relative Value
Base Case
0.6
DKK
Overvaluation 40%
Multiples Across Competitors
BIOPOR Competitors Multiples
Bioporto A/S Competitors
Bioporto A/S Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DK |
|
Bioporto A/S
CSE:BIOPOR
|
454.7m DKK | 12.4 | -5.2 | -4.8 | -4.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
402.4B USD | 6.7 | 171.4 | 16.6 | 23.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
199.5B USD | 5.4 | 25.8 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
189.8B USD | 6.5 | 23.3 | 15.9 | 15.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.5B USD | 10.1 | 32.3 | 23.7 | 24.7 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.8B USD | 5.8 | 18.5 | 14 | 16 | |
| AU |
|
CSL Ltd
ASX:CSL
|
74.1B AUD | 3.3 | 17.2 | 11.8 | 14.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR | 14.3 | 33.5 | 57.2 | 58.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
